IRD: Opus Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Stocks in this Quantisnow insightHealth Care
Historical context for IRD
Across the 4 sessions after earlier IRD headlines, the stock closed higher 1 times and lower 3 times, with a median move of 2.6% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IRD | SPY |
|---|---|---|---|
| Nov 12, 2025 | Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update | -2.5% | +0.1% |
| Nov 5, 2025 | Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | -2.3% | +0.3% |
| Nov 3, 2025 | Opus Genetics Featured on Good Morning America Spotlighting Breakthrough Gene Therapy Restoring Sight in Patients with Inherited Blindness | -7.0% | +0.2% |
| Oct 29, 2025 | Wedbush initiated coverage on Opus Genetics with a new price target | +2.6% | +0.0% |
Quantisnow market dataNASDAQ
IRD
Opus Genetics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for IRD
Full IRD profile on Quantisnow Follow IRD and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time